Last updated on January 2020

Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma


Brief description of study

This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.

Detailed Study Description

This is open-label, single arm study designed to evaluate the safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 66 subjects will be dosed in Japan. Subjects will receive tezepelumab administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.

Clinical Study Identifier: NCT04048343

Find a site near you

Start Over

Research Site

Shinjuku-ku, Japan
3.41miles
  Connect »

Research Site

Chuo-ku, Japan
7.83miles
  Connect »

Research Site

Shinagawa-ku, Japan
9.79miles
  Connect »